NASDAQ:PCRX - Pacira Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pacira Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $43.33 -0.13 (-0.30 %) (As of 01/29/2020 04:00 PM ET) Add Compare Today's Range$42.85Now: $43.33▼$43.7350-Day Range$42.40MA: $44.53▼$46.7852-Week Range$34.64Now: $43.33▼$49.50Volume333,671 shsAverage Volume456,363 shsMarket Capitalization$1.81 billionP/E Ratio1,083.25Dividend YieldN/ABeta1.16 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PCRX Previous Symbol CUSIP69512710 CIK1396814 Webhttp://www.pacira.com/ Phone973-254-3560Debt Debt-to-Equity Ratio0.98 Current Ratio3.95 Quick Ratio3.32Price-To-Earnings Trailing P/E Ratio1,083.25 Forward P/E Ratio60.18 P/E Growth1.1 Sales & Book Value Annual Sales$337.28 million Price / Sales5.36 Cash Flow$0.95 per share Price / Cash Flow45.83 Book Value$7.81 per share Price / Book5.55Profitability EPS (Most Recent Fiscal Year)$0.29 Net Income$-470,000.00 Net Margins0.55% Return on Equity10.19% Return on Assets4.54%Miscellaneous Employees518 Outstanding Shares41,730,000Market Cap$1.81 billion Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive PCRX News and Ratings via Email Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PCRX Rates by TradingView Pacira Biosciences (NASDAQ:PCRX) Frequently Asked Questions What is Pacira Biosciences' stock symbol? Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX." How were Pacira Biosciences' earnings last quarter? Pacira Biosciences Inc (NASDAQ:PCRX) released its quarterly earnings data on Thursday, November, 7th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.13 by $0.35. The business earned $104.69 million during the quarter, compared to analysts' expectations of $104.88 million. Pacira Biosciences had a return on equity of 10.19% and a net margin of 0.55%. The business's quarterly revenue was up 25.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.31 EPS. View Pacira Biosciences' Earnings History. When is Pacira Biosciences' next earnings date? Pacira Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Pacira Biosciences. What guidance has Pacira Biosciences issued on next quarter's earnings? Pacira Biosciences issued an update on its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $421-421 million, compared to the consensus revenue estimate of $418.06 million. What price target have analysts set for PCRX? 13 brokerages have issued 1 year price objectives for Pacira Biosciences' shares. Their forecasts range from $38.00 to $85.00. On average, they expect Pacira Biosciences' share price to reach $53.73 in the next year. This suggests a possible upside of 24.0% from the stock's current price. View Analyst Price Targets for Pacira Biosciences. What is the consensus analysts' recommendation for Pacira Biosciences? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 1 sell rating, 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pacira Biosciences. What are Wall Street analysts saying about Pacira Biosciences stock? Here are some recent quotes from research analysts about Pacira Biosciences stock: 1. According to Zacks Investment Research, "Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience in April 2019 following which, it added the latter’s iovera system to its portfolio. Its top line mainly comprises contribution from its marketed drug Exparel, which led to solid revenues since its approval. The drug’s label expansion to include administration via nerve block for prolonged regional analgesia is a positive for the company as it will further boost sales. Pacira’s agreement with Nuance for the development and commercialization of Exparel in China is also an upside. Shares of the company have outperformed the industry in the past year. The company also remains heavily dependent on Exparel for growth. Therefore, any setback for the drug will severely hurt the stock." (1/8/2020) 2. Stifel Nicolaus analysts commented, "We are upgrading shares of PCRX to Hold as we believe the near-term competitive threat from HRTX’s HTX-011 will be less of a factor over the next 12 months and the recent strength in the stock indicates to us that the stock is fairly valued at these levels. While PCRX’s Exparel revenues came in a little shy of 1Q19 consensus, we believe the recent price increase on Exparel, the lack of a competitive entry from HRTX and the favorable reimbursement scheme in the ASC setting should allow PCRX to achieve its 2019 Exparel guidance, in our view. Our revised 2019 Exparel estimates are now at the midpoint of management’s guidance of ~$400-$410 million (vs. consensus of ~$403 million). Additionally, we incorporate PCRX’s recent acquisition, Iovera, into our model and raise our target price to $45 a share." (5/2/2019) Has Pacira Biosciences been receiving favorable news coverage? Media stories about PCRX stock have been trending very positive on Wednesday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pacira Biosciences earned a media sentiment score of 3.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the near term. View News Stories for Pacira Biosciences. Who are some of Pacira Biosciences' key competitors? Some companies that are related to Pacira Biosciences include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX). What other stocks do shareholders of Pacira Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), Celgene (CELG), ACADIA Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Incyte (INCY), Micron Technology (MU), Bausch Health Companies (BHC), Exelixis (EXEL), Neurocrine Biosciences (NBIX) and Netflix (NFLX). Who are Pacira Biosciences' key executives? Pacira Biosciences' management team includes the folowing people: Mr. David M. Stack, Chairman & CEO (Age 69)Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 58)Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 45)Dr. Richard Scranton M.D., MPH, Chief Medical Officer (Age 52)Mr. Dennis McLoughlin, Chief Commercial Officer (Age 53) Who are Pacira Biosciences' major shareholders? Pacira Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.00%), Peregrine Capital Management LLC (0.80%), California Public Employees Retirement System (0.40%), Legacy Capital Partners Inc. (0.11%), New York State Teachers Retirement System (0.08%) and State of Alaska Department of Revenue (0.08%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings and Richard Scranton. View Institutional Ownership Trends for Pacira Biosciences. Which institutional investors are selling Pacira Biosciences stock? PCRX stock was sold by a variety of institutional investors in the last quarter, including Arizona State Retirement System, Rice Hall James & Associates LLC, Peregrine Capital Management LLC and Legacy Capital Partners Inc.. Company insiders that have sold Pacira Biosciences company stock in the last year include Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Biosciences. Which institutional investors are buying Pacira Biosciences stock? PCRX stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, New York State Teachers Retirement System, Louisiana State Employees Retirement System, Everence Capital Management Inc., Rothschild Investment Corp IL, Bouchey Financial Group Ltd, State of Alaska Department of Revenue and Nisa Investment Advisors LLC. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace and Mark A Kronenfeld. View Insider Buying and Selling for Pacira Biosciences. How do I buy shares of Pacira Biosciences? Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Pacira Biosciences' stock price today? One share of PCRX stock can currently be purchased for approximately $43.33. How big of a company is Pacira Biosciences? Pacira Biosciences has a market capitalization of $1.81 billion and generates $337.28 million in revenue each year. The company earns $-470,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe.View Additional Information About Pacira Biosciences. What is Pacira Biosciences' official website? The official website for Pacira Biosciences is http://www.pacira.com/. How can I contact Pacira Biosciences? Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected] MarketBeat Community Rating for Pacira Biosciences (NASDAQ PCRX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 702 (Vote Outperform)Underperform Votes: 524 (Vote Underperform)Total Votes: 1,226MarketBeat's community ratings are surveys of what our community members think about Pacira Biosciences and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/29/2020 by MarketBeat.com StaffFeatured Article: Why do earnings reports matter?
